Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21805954 | 0.89 | HSD17B10 (0.34) | ALDH1A1HPGDGLASMN1; SMN2HSD17B10 | |
| SCHEMBL21805952 | 0.87 | HSD17B10 (0.33) | ALDH1A1HPGDGLASMN1; SMN2HSD17B10 | |
| SCHEMBL22419059 | 0.86 | DDR1 (0.33) | DDR1 | |
| SCHEMBL20455829 | 0.86 | SMN1; SMN2 (0.35) | ALDH1A1HPGDSMN1; SMN2KDM4EDDR1 | |
| SCHEMBL20468293 | 0.84 | ALDH1A1 (0.31) | ALDH1A1HPGDGLASMN1; SMN2HSD17B10 | |
| SCHEMBL20465984 | 0.83 | ALDH1A1 (0.30) | ALDH1A1HPGDGLASMN1; SMN2 | |
| SCHEMBL22280676 | 0.83 | FEN1 (0.32) | DDR1 | |
| SCHEMBL29521486 | 0.83 | DDR1 (0.35) | DDR1 | |
| SCHEMBL20455821 | 0.83 | DDR1 (0.35) | DDR1 | |
| SCHEMBL17949562 | 0.81 | SMN1; SMN2 (0.32) | ALDH1A1HPGDGLASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020058010-A1 | PESTICIDAL MIXTURES COMPRISING A MESOIONIC COMPOUND | BASF SE (DE) | 2020-03-26 | — | — | WO | claimed |
| CN-110248942-B | Process for preparing halogenated imidazopyridine derivatives | 拜耳公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3577114-B1 | METHOD FOR THE PREPARATION OF HALOGENATED IMIDAZOPYRIDINE DERIVATIVES | BAYER AG (DE) | 2021-11-10 | — | — | EP | disclosed |
| US-11072609-B2 | Method for preparing halogenated imidazopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-07-27 | — | — | US | disclosed |
| US-11072609-B2 | Method for preparing halogenated imidazopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20210094947-A1 | METHOD FOR PREPARING HALOGENATED IMIDAZOPYRIDINE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2021-04-01 | — | — | US | disclosed |
| US-20210094947-A1 | METHOD FOR PREPARING HALOGENATED IMIDAZOPYRIDINE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2021-04-01 | — | — | US | disclosed |
| US-10772332-B2 | 2-(het)aryl-substituted fused heterocycle derivatives as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-15 | — | — | US | disclosed |
| US-20200236940-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-30 | — | — | US | disclosed |
| WO-2020058010-A1 | PESTICIDAL MIXTURES COMPRISING A MESOIONIC COMPOUND | BASF SE (DE) | 2020-03-26 | — | — | WO | disclosed |
| WO-2018141955-A1 | PROCESS FOR PREPARING HALOGENATED IMIDAZOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772332-B2 | 2-(het)aryl-substituted fused heterocycle derivatives as pesticides | CYP4X1, CYP1A1, CYP1A2 | ALDH1A1 591/4885HPGD 508/4885GLA 3187/4885 |
| US-20210094947-A1 | METHOD FOR PREPARING HALOGENATED IMIDAZOPYRIDINE DERIVATIVES | CYP2F1, CYP2D6, POLR2A | ALDH1A1 853/4885HPGD 1461/4885GLA 3154/4885 |
| US-11072609-B2 | Method for preparing halogenated imidazopyridine derivatives | CYP2F1, CYP2D6, POLR2A | ALDH1A1 853/4885HPGD 1461/4885GLA 3154/4885 |
| US-20200236940-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED HETEROCYCLE DERIVATIVES AS PESTICIDES | CYP4X1, CYP1A1, CYP1A2 | ALDH1A1 591/4885HPGD 508/4885GLA 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.